Bio-Rad Laboratories, Inc.Class A earnings per share and revenue
On 29 de out. de 2025, BIO reported earnings of 2.25 USD per share (EPS) for Q3 25, beating the estimate of 1.95 USD, resulting in a 15.74% surprise. Revenue reached 653.00 milhão, compared to an expected 657.81 milhão, with a -0.73% difference. The market reacted with a -4.65% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analistas forecast an EPS of 2.77 USD, with revenue projected to reach 705.51 milhão USD, implying an aumentar of 23.11% EPS, and aumentar of 8.04% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Neogen Corp
Report Date
08 de jan. de 2026 Para Q2 26
Estimativa
$0.05
Real
$0.10
Surpresa
+78.25%
Tilray Brands, Inc. Common Stock
Report Date
08 de jan. de 2026 Para Q2 26
Estimativa
-$0.20
Real
-$0.41
Surpresa
-100.98%
FAQ
What were Bio-Rad Laboratories, Inc.Class A's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Bio-Rad Laboratories, Inc.Class A reported EPS of $2.25, beating estimates by 15.74%, and revenue of $653.00M, -0.73% below expectations.
How did the market react to Bio-Rad Laboratories, Inc.Class A's Q3 2025 earnings?
The stock price moved down -4.65%, changed from $319.47 before the earnings release to $304.61 the day after.
When is Bio-Rad Laboratories, Inc.Class A expected to report next?
The next earning report is scheduled for 11 de fev. de 2026.
What are the forecasts for Bio-Rad Laboratories, Inc.Class A's next earnings report?
Based on 6
analistas, Bio-Rad Laboratories, Inc.Class A is expected to report EPS of $2.77 and revenue of $705.51M for Q4 2025.